Bluebird Bio Stumbles Over Secondary Offering
Bluebird Bio saw its shares dip on Wednesday after the firm announced the pricing of a secondary offering of more than 3 million shares.
Bluebird Bio saw its shares dip on Wednesday after the firm announced the pricing of a secondary offering of more than 3 million shares.
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
Proteostasis Therapeutics shares absolutely exploded in Tuesday’s session, more than doubling after the firm reported positive study results.
The November 30 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks was mixed.
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
A generic version of Viagra is coming to America, but will existing customers be willing to switch over to a generic version of the pill?
Blueprint Medicines watched its shares make a solid gain on Monday morning after the firm announced results for its ongoing early-stage trial for advanced systemic mastocytosis.
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
Denali Therapeutics entered the markets with a bang on Friday. In its initial public offering, the company priced its almost 14 million shares within the expected range.
Radius Health shares climbed higher on Friday after the firm provided an update on its early-stage clinical study in patients with estrogen receptor positive breast cancer.
More than half of Americans now believe that government has a responsibility to make sure that all Americans have health care coverage.
SteadyMed saw its shares make an incredibly gain to close out the week, after a positive meeting with the FDA.
Alexion Pharmaceuticals shares saw a handy gain early on Friday after the New York Times reported that there might be some increasing activist movement in the stock.
Sage Therapeutics saw its shares make an incredible gain on Thursday after the firm announced positive top-line results from its midstage trial.
Arrowhead Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm presented new data from its midstage study for the treatment of hepatitis B infection.